Wellness & Lifestyle

DiaGen AI is at the forefront of transforming drug discovery and diagnostics through its proprietary AI technology. The platform scales foundational and deep generative AI models to utilize large proprietary data, aiming to improve human longevity. It offers an internal platform and products across three distinct verticals. Key offerings include Molecule Optimizer, Peptide Research Efficacy/Precision Technology, Target Identification Technology, High Throughput Virtual Screening, and AI Designed Biomarker Binders for Diagnostics. With a team boasting over 100 years of combined experience, DiaGen AI is dedicated to making the drug discovery process faster, more efficient, and highly accurate.

AI4b.io is a collaborative research program between DSM and Delft University of Technology, dedicated to 'AI for Bioscience'. The lab aims to develop and apply novel AI technologies, methods, and algorithms to strengthen the effectiveness and efficiency of research and business processes within the biotech industry. Their work spans various projects, including AI-assisted fermentation digital twins, smart plant scheduling, AI for self-driving laboratories, machine learning for iterative metabolic engineering, and microbiome-based precision feed. The initiative also supports the development of Planet B.io, an open innovation ecosystem for industrial biotech, fostering advancements from large-scale manufacturing to lab operations and metabolic levels.

Evariste is an AI-enabled drug discovery company focused on developing small molecule therapeutics for synthetic lethal oncology indications. Its proprietary AI platform, Frobenius, leverages advanced mathematical modeling and machine learning to identify novel drug targets and biomarkers, and to design high-quality, differentiated small molecule candidates. Frobenius integrates multi-modal data for target identification and utilizes machine learning models for efficient small molecule design and scoring, even with small, noisy datasets. The platform aims to de-risk and progress projects with unrivaled efficiency, leading to a pipeline of precision oncology therapeutics including best-in-class inhibitors for validated targets and first-in-class inhibitors for novel synthetic lethal targets.

InterVenn Biosciences leverages AI to decode the glycoproteome, offering a powerful platform for clinical applications. Their GlycoVision platform is designed to facilitate advancements in early disease screening and diagnostics. This technology is accessible to industry partners, providing a sophisticated tool for discovering novel biomarkers from serum or plasma samples. By focusing on the complex world of glycans, InterVenn aims to unlock new insights into disease mechanisms and improve patient outcomes through precision medicine.

Redesign Science is a platform biotech company that leverages advanced computational methods for drug discovery. The company simulates biomolecular systems from first principles using physics-based atomic-level molecular dynamics. Their proprietary NUVO™ technology platform integrates physics simulation with generative AI to power an internal therapeutics pipeline. This approach enables the development of first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™), aiming to control cellular biology by targeting the structural protein interactome. Redesign Science focuses on dynamic structure-based drug discovery, tackling complexity in therapeutic programs with rapid progress.

Medvolt is an AI-driven platform revolutionizing early-stage drug discovery and development by democratizing access to cutting-edge generative AI and advanced physics-based simulation technology. Its in silico platform, MedGraph, empowers the generation of novel insights through efficient, resource-optimized pipelines, translating into tangible experimental results. Key features include interpretable and data-centric AI models trained on curated domain data, an affordable and enterprise-class modular platform, and multi-domain expertise. Medvolt offers solutions for small and large molecule drug discovery, knowledge curation, and peptide therapeutics, aiming to reduce costs and significantly boost success rates in pharmaceutical research.

BullFrog AI is an advanced AI platform designed to accelerate biopharma drug discovery and clinical development. It leverages explainable AI, graph analytics, and data harmonization tools to transform raw, fragmented biomedical data into clean, AI-ready assets. The platform features bfPREP™ for data preparation and harmonization, bfLEAP® for uncovering biologically meaningful patterns and identifying patient subgroups, and an AI Decision Support system for prioritizing drug targets and optimizing trial design. BullFrog AI aims to provide reliable insights, understand disease heterogeneity, and build risk-balanced R&D portfolios, ultimately mitigating risk and elevating precision medicine.

CadenceAI is an AI-powered platform designed to bring financial clarity and control to clinical trials. It helps biotech and pharmaceutical companies predict risks, prevent budget overruns, and keep science moving forward. The platform unifies contracts, budgets, and timelines with AI, offering financial oversight, predicting overages early, and suggesting reallocation strategies in real time. CadenceAI also features a Contract, Invoice & Compliance Engine that flags risky clauses, tracks payment mismatches, and ensures compliance across vendors and studies. Acting as an end-to-end project driver, it maps dependencies across R&D, clinical, and regulatory milestones, predicts delays, and recommends mitigation steps, effectively automating manual work and reducing costs.

Pathos is an AI-enabled, clinical-stage biotech company focused on redefining drug development for precision oncology. It integrates advanced AI technology, biological modeling, and the largest collection of oncology patient data to make clinical trials smarter, faster, and more precise. Pathos addresses the problem of high failure rates in early clinical trials by ensuring therapies are tested in the right patient subgroups. The platform leverages millions of oncology records, connecting genomics, transcriptomics, imaging, text, and longitudinal clinical outcomes. Proprietary data models with thousands of AI agents analyze this data, simulate trial scenarios, and identify patient populations most likely to respond, leading to higher success rates and faster timelines in drug development.

CliniNote is an AI-driven platform designed to unlock the power of clinical data by streamlining documentation and data collection within healthcare settings. It allows for effortless collection of structured data for clinical trials and real-world evidence (RWE), directly within existing Electronic Health Record (EHR) systems. The tool boosts efficiency by enabling users to create, customize, and manage dynamic note templates, reducing repetitive tasks and ensuring compliance with real-time error detection and validation. CliniNote automatically structures data during documentation, facilitating easier reporting and analysis with one-click exports. Its browser extension offers quick setup and minimal integration effort, making it accessible without complex IT processes. The platform is trusted by leaders in healthcare for its ability to deliver real-time, high-quality, and interoperable medical data, driving innovation in research and drug development without burdening clinicians.

ImagoAI is revolutionizing the food testing industry by leveraging cutting-edge AI and Hyperspectral Imaging technology to provide the world's fastest mycotoxin tests. This innovative solution enables on-site, real-time food testing, delivering results in under 30 seconds without the need for consumables. The platform can test for mycotoxins, vitamins, and particle sizes in various food products like corn, DDGS, premix, and breakfast cereals. ImagoAI's GALAXY system offers multiple tests at a significantly reduced cost, helping to mitigate risks and save up to 90% in labor time. The technology captures invisible chemical signatures at every pixel, powered by AI models trained on millions of hyperspectral pixels and thousands of samples, ensuring accuracy and ease of use.

Pienomial offers an enterprise AI platform, Knolens, designed for organizations where accuracy and explainability are paramount. It provides a structured knowledge layer from verifiable sources, ensuring zero hallucination and full traceability for every insight. The platform is built on three foundational principles: knowledge as a private enterprise asset, secure and LLM-agnostic architecture, and flexibility in knowledge automation. Knolens supports various industries including Life Sciences, Financial Services, Consulting, and Public Sector, offering solutions for regulatory submissions, risk analysis, client-ready insights, and policy analysis. It differentiates itself with unlimited context, domain-aware intelligence, no dependency on black-box AI, and enterprise-grade security, optimizing for verifiable intelligence and audit-ready outputs.

Manifold is an AI platform specifically designed for the life sciences sector, aiming to accelerate the journey of medicines from initial discovery to market. It offers a comprehensive suite of tools including Agent OS for automating R&D tasks, AI Cohort Explorer for building research-ready cohorts, and AI Analysis Agent for transforming natural language questions into analyses. The platform emphasizes collaboration with features like a Collaborative Workbench and Dataset Access Controls, while supporting various tools such as Python, R, and nf-core pipelines. Manifold also provides robust data management capabilities, including AI-powered data cataloging, engineering, and dashboards for multimodal biomedical data. It ensures data protection through built-in guardrails, enterprise-grade security, and compliance with standards like NIST 800-171, TX-RAMP, SOC 2 Type II, HIPAA, and GDPR.

Bindwell is at the forefront of agricultural innovation, leveraging AI to design and develop next-generation pesticides. The company addresses critical issues in the agrochemical industry, such as increasing pest resistance and the environmental impact of current solutions. By building neural networks to replace traditional wet lab processes, Bindwell conducts high-throughput assays in its San Carlos wet lab to generate training data for its models. This computational approach, inspired by Richard Sutton's "The Bitter Lesson," accelerates the discovery of novel active ingredients. Bindwell is currently focused on developing its first pesticide for the invasive pest Spodoptera frugiperda, with plans for further expansion. The company is backed by prominent investors including Y Combinator and General Catalyst.

Basil Systems offers an AI-powered platform designed for the life sciences industry, specifically targeting pharmaceutical and MedTech organizations. It integrates commercial, regulatory, medical affairs, quality, and safety data into a single intelligence platform, providing hourly updates across global markets and AI-validated insights. With over 30 years of historical data, Basil Systems enables teams to transition from reactive to proactive strategies, significantly compressing response times. The platform supports various functions, including identifying actionable market opportunities, accelerating regulatory submissions, strengthening scientific engagement, mastering post-market surveillance, and overcoming competitive threats. It boasts over 700 million records, real-time monitoring, and rapid implementation.

InterLink AI, a company previously focused on data-driven pharmacy technology, has formally ceased its operations. The assets of the business have been acquired by Phoenix Pharmatech. Customers and interested parties are directed to Phoenix Pharmatech's website at phoenixpharmatech.com for any inquiries or to explore their offerings. The original InterLink AI aimed to provide solutions for pharmacies to enhance operational efficiency and prescription accuracy, with products designed for medication identification, dispensing, telepharmacy verification, and inventory management. The company's goal was to improve patient safety and overall pharmacy experiences through its AI-powered technologies.

Blank Bio is at the forefront of precision medicine, utilizing advanced RNA intelligence to transform drug development and clinical trials. The platform employs foundation models that integrate isoform, mutation, and expression signals from RNA, moving beyond traditional gene-level counts. This comprehensive approach allows for the identification of complex, multi-gene patterns that are often missed by conventional methods, leading to improved patient stratification, enhanced diagnostic accuracy, and more effective therapeutic design. Blank Bio's technology supports applications such as building multi-gene signatures for trial enrichment, refining disease classification, discovering new therapeutic targets, and optimizing RNA-based therapeutics. It also offers biosecurity monitoring through automated characterization of biological threats.

immunoMAPs is a premier computational platform designed to advance immunotherapy development through high-quality, end-to-end immunological data analysis. It assists small and medium enterprises (SMEs) in making data-driven decisions across the entire immunotherapies development life cycle. The platform utilizes advanced AI and machine learning models for immuno-informatics, enabling the identification of tumor antigens with immunopeptidomics, prediction of therapy responses to immune-checkpoint inhibitors, comprehensive TME analysis, and adverse event predictions. By integrating multi-omics datasets, immunoMAPs enhances the precision of peptide predictions and supports the design of novel immunotherapies, ultimately reducing risks in preclinical and clinical development.

immunitoAI is a TechBio company specializing in the development of AI-generated novel antibody therapeutics. Their platform focuses on 'Design over Discovery,' creating antibodies in silico without relying on biological sources, which aims to increase efficiency and expand the antibody space beyond natural repertoires. The company emphasizes 'Drug-First Antibodies,' embedding pre-defined drug properties at the inception of the design process to minimize the exploratory phase in drug developability. Utilizing a 'Structure-First AI Platform,' their neural networks are trained on shape complementarity for precise, target-specific design, optimizing affinity and specificity, and potentially opening possibilities for previously undruggable targets. immunitoAI's vision is to make antibody therapy the norm by unleashing the full potential of antibody-based biological drugs.

PaddleHelix is an advanced bio-computing platform developed by PaddlePaddle, designed to accelerate research and development in drug discovery, vaccine design, and precision medicine. It utilizes state-of-the-art machine learning approaches, particularly deep neural networks, to offer solutions for complex biological problems. Key functionalities include large-scale pre-training models for compounds and proteins, molecular property prediction, drug-target affinity prediction, and molecular generation. For vaccine design, it provides RNA design algorithms like LinearFold and LinearPartition. The platform also supports precision medicine through applications like drug-drug synergy. Recent advancements include HelixFold3.2 for significant improvements in protein-related tasks and structural quality, HelixDock for protein-ligand structure prediction, and HelixFold-Multimer for protein complex structure prediction. PaddleHelix offers both open-source code for non-commercial academic research and paid API access for high-throughput use.

BioSymetrics, a Lunai Bioworks company, is a phenomics-driven drug discovery company that leverages AI and in vivo validation to identify high-confidence targets and precision medicines. They integrate massive and dynamic clinical and experimental data, including over 77 million longitudinal patient records and 1 million genomic profiles, with machine learning to make predictions. The company focuses on neurological, cardiometabolic, and rare diseases, with lead programs in common and rare epilepsies. Their approach involves connecting disease phenotype and genotype data between humans and model systems, followed by high-content in vivo validation of new targets, such as their KCC2 Epilepsy program which uses computer vision algorithms to analyze zebrafish video data.

Compass Bioinformatics Inc. presents InheriNext, an AI-powered platform designed to streamline next-generation sequencing (NGS) analysis for inherited diseases. InheriNext features a cutting-edge variant ranking algorithm, intuitive design, and validated accuracy, empowering scientists and clinicians in hospitals and research laboratories. The platform supports data from most automated sequencing instruments, offering secure and optimized pipelines for complex variant calling from FASTQ or VCF formats. Users can identify and rank causative variants based on clinical phenotypes, in silico gene panels, or customized filters. InheriNext also provides custom report functionality for inherited diseases, including summaries and support for categorized variants. It automates routine tasks with accuracy and efficiency, ensuring consistency through baked-in ACMG guidelines and offering transparency by revealing all supporting evidence for its conclusions.

MiBA (Meaningful Insights Biotech Analytics) is a healthcare AI technology company specializing in oncology. It offers AI-powered data solutions to enhance oncology innovation and improve patient outcomes. The platform provides remarkable visibility into oncology care through a comprehensive, geographically diverse network of providers, consolidating all data assets in real-time with nightly updates. Key offerings include real-time intelligence for clinical trials, business intelligence with a proprietary Market Basket solution, targeted education for providers, and custom data solutions. MiBA's advanced AI technology synthesizes multimodal data to uncover meaningful patterns and insights, ensuring high precision and recall for reliable intelligence.

Reach Industries focuses on building frontier technologies and designing systems that prioritize human collaboration. Their initial venture is in the science sector, where they've developed Lumi, the first Visual AI Copilot for science. Lumi aims to upgrade scientific processes by addressing the complexities and heavy regulations within laboratories, which often rely on manual record-keeping and human observation for critical tasks. By integrating AI, Lumi seeks to improve efficiency and accuracy in scientific research, allowing scientists to concentrate on higher-level work. The company's vision is to foster a future where humans and machines work together seamlessly, enhancing industries and unlocking human potential.